Actavis Launches Generic Viagra® in Europe as Patents Expire
(Thomson Reuters ONE) -
ZUG, SWITZERLAND - June 24, 2013 - Actavis, Inc. (NYSE: ACT), a leading global
specialty pharmaceutical company, today announced that it has launched
Sildenafil Actavis 25 mg, 50 mg and 100 mg tablets in 11 major Western-European
markets on market formation. Sildenafil Actavis, the generic equivalent of
Pfizer's Viagra(®), is prescribed to treat erectile dysfunction.
Actavis' product was launched immediately after the patents expired in Austria,
Denmark, France, Germany, Ireland, Italy, The Netherlands, Spain, Sweden,
Switzerland and the United Kingdom.
Actavis first launched Sildenafil tablets in Bulgaria in June 2009 - the first
generic Sildenafil to enter the patent-free Bulgarian market - and has since
launched the product in various other patent-free markets in Europe, including
Iceland and Malta. Sildenafil Actavis is manufactured and developed by Actavis,
in Malta and Iceland respectively.
According to IMS Health, Viagra(®) had sales of EUR382.2 million in Europe for
the 12 months ending March 31, 2013.
About Actavis
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand and
biosimilar products. Actavis has global headquarters in Parsippany, New Jersey,
USA.
Operating as Actavis Pharma, Actavis develops, manufactures and markets generic,
branded generic, legacy brands and Over-the-Counter (OTC) products in more than
60 countries.
Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical
business focused in the Urology and Women's Health therapeutic categories.
Actavis Specialty Brands also has a portfolio of five biosimilar products in
development in Women's Health and Oncology. Actavis Global Operations has more
than 30 manufacturing and distribution facilities around the world, and includes
Anda, Inc., a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis' Web site at
www.actavis.com.
Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual performance.
Actual results may differ materially from Actavis' current expectations
depending upon a number of factors, risks and uncertainties affecting Actavis'
business. These factors include, among others, the impact of competitive
products and pricing; the timing and success of product launches; difficulties
or delays in manufacturing; the availability and pricing of third party sourced
products and materials; successful compliance with governmental laws, rules and
regulations applicable to Actavis and its third party manufacturers' facilities,
products and/or businesses; changes in the laws and regulations affecting among
other things, pricing and reimbursement of pharmaceutical products; and such
other risks and uncertainties detailed in Actavis' periodic public filings with
the Securities and Exchange Commission, including but not limiting to Actavis'
Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and Actavis'
annual report on Form 10-K for the year ended December 31, 2012. Except as
expressly required by law, Actavis disclaims any intent or obligation to update
these forward-looking statements.
Viagra(®) is a registered trademark of Pfizer, Inc.
CONTACTS:
Investors:
Lisa DeFrancesco
+1 862 261 7152
Media:
Elisabet Hjaltadottir
+41 79 909 7370
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actavis via Thomson Reuters ONE
[HUG#1711439]
Unternehmensinformation / Kurzprofil:
Datum: 24.06.2013 - 13:41 Uhr
Sprache: Deutsch
News-ID 272526
Anzahl Zeichen: 4619
contact information:
Town:
Zug
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actavis Launches Generic Viagra® in Europe as Patents Expire"
steht unter der journalistisch-redaktionellen Verantwortung von
Actavis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
